Tomoko Oeda

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Masayuki Tahara, Tomoko Oeda, Kazumasa Okada et al. · The Lancet Neurology · 2020 · 347 citations

Ocular Disease, Ophthalmology, Eye Health +5

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial

Hideyuki Sawada, Tomoko Oeda, Sadako Kuno et al. · PLoS ONE · 2010 · 139 citations · Full text

Case–control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan

Yoshihiro Miyake, Keiko Tanaka, Wakaba Fukushima et al. · Journal of the Neurological Sciences · 2010 · 137 citations

Metabolic Syndrome, Hypertension, Diabetes Epidemiology +13

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Günter U. Höglinger, Irene Litvan, Nuno Mendonça et al. · The Lancet Neurology · 2021 · 130 citations · Full text

Clinical Trials, Progressive Supranuclear Palsy, Placebo-controlled Trial +7

Dietary intake of antioxidant vitamins and risk of Parkinson’s disease: a case–control study in Japan

Yoshihiro Miyake, Wakaba Fukushima, Keiko Tanaka et al. · European Journal of Neurology · 2010 · 117 citations